Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CapeOX plus bevacizumab for recurrent HCC after liver transplantation with prior TKI failure
ChiCTR2600126870Phase 2Recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoint: objective response rate. Started Jun 2026; status: recruiting.
02
Drugs
capecitabineoxaliplatinbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600126870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126870.